Risk mitigation during concizumab prophylaxis in phase 3 clinical trials in patients with hemophilia a/b with and without inhibitors: management of breakthrough bleeds and dose optimization
AMERICAN JOURNAL OF HEMATOLOGY(2023)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要